Kyntra Bio, Inc. (KYNB)
NASDAQ: KYNB · Real-Time Price · USD
7.15
+0.14 (2.00%)
Aug 19, 2026, 4:00 PM EDT - Market closed
Kyntra Bio Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 4.62 | 6.44 | 29.62 | 46.8 | 140.73 | 235.31 | |
Revenue Growth | -37.16% | -78.26% | -36.71% | -66.74% | -40.19% | 33.46% |
Cost of Revenue | 27.19 | 24.07 | 111.25 | 295.07 | 299.95 | 449.19 |
Gross Profit | -22.58 | -17.63 | -81.63 | -248.27 | -159.21 | -213.88 |
Selling, General & Admin | 27.67 | 27.71 | 49.33 | 86.48 | 141.81 | 134.65 |
Operating Expenses | 27.67 | 27.71 | 49.33 | 86.48 | 141.81 | 134.65 |
Operating Income | -50.25 | -45.34 | -130.96 | -334.75 | -301.03 | -348.53 |
Interest Expense | -9.29 | -8.76 | -8.25 | -8.1 | -1.44 | -1.08 |
Interest & Investment Income | 4.33 | 2.94 | 5.3 | 7.87 | 7.6 | - |
Earnings From Equity Investments | - | - | - | - | 1.57 | 1.01 |
Other Non Operating Income (Expenses) | - | - | - | - | - | -1.08 |
EBT Excluding Unusual Items | -55.2 | -51.16 | -133.91 | -334.98 | -293.29 | -349.68 |
Merger & Restructuring Charges | -0.07 | -0.55 | -19.45 | -12.61 | - | - |
Gain (Loss) on Sale of Investments | - | - | - | -0.27 | -0.01 | - |
Other Unusual Items | -6.58 | -6.58 | - | - | - | - |
Pretax Income | -30.91 | -58.29 | -153.37 | -323.22 | -293.3 | -289.68 |
Income Tax Expense | -0 | -0.09 | -0.27 | -0.25 | 0.36 | 0.35 |
Earnings From Continuing Operations | -30.91 | -58.2 | -153.1 | -322.97 | -293.65 | -290.02 |
Earnings From Discontinued Operations | 214.11 | 241.66 | 105.52 | 38.74 | - | - |
Net Income | 183.19 | 183.45 | -47.58 | -284.23 | -293.65 | -290.02 |
Net Income to Common | 183.19 | 183.45 | -47.58 | -284.23 | -293.65 | -290.02 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 4 | 4 | 4 | 4 | 4 | 4 |
Shares Outstanding (Diluted) | 4 | 4 | 4 | 4 | 4 | 4 |
Shares Change | 0.32% | 1.02% | 2.82% | 3.98% | 1.33% | 2.78% |
EPS (Basic) | 45.27 | 45.38 | -11.89 | -73.03 | -78.45 | -78.51 |
EPS (Diluted) | 45.27 | 45.38 | -11.89 | -73.03 | -78.45 | -78.51 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -38.06 | -4.81 | -138.27 | -317.54 | -149.67 | -87.42 |
Free Cash Flow Per Share | -9.40 | -1.19 | -34.55 | -81.58 | -39.98 | -23.66 |
Gross Margin | - | -273.80% | -275.59% | - | -113.13% | -90.89% |
Operating Margin | -1088.56% | -704.07% | -442.13% | -715.23% | -213.90% | -148.12% |
Profit Margin | 3968.63% | 2848.63% | -160.63% | -607.29% | -208.66% | -123.25% |
Free Cash Flow Margin | -824.57% | -74.72% | -466.78% | -678.46% | -106.35% | -37.15% |
EBITDA | -50.04 | -44.59 | -128.27 | -324.82 | -290.42 | -333.72 |
EBITDA Margin | - | - | - | - | -206.36% | -141.82% |
D&A For EBITDA | 0.21 | 0.75 | 2.69 | 9.93 | 10.6 | 14.81 |
EBIT | -50.25 | -45.34 | -130.96 | -334.75 | -301.03 | -348.53 |
EBIT Margin | - | - | - | - | -213.90% | -148.12% |
Revenue as Reported | 4.62 | 6.44 | 29.62 | 46.8 | 140.73 | 235.31 |